Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05360953
Other study ID # ClonDo-PTSD
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 6, 2022
Est. completion date April 1, 2025

Study information

Verified date April 2022
Source Charite University, Berlin, Germany
Contact Stefan Roepke, MD
Phone 004930450517545
Email stefan.roepke@charite.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized controlled trial will test the hypothesis that oral Clonidine or Doxazosin improves nightmares (primary outcome), other PTSD symptoms and psychopathology (secondary outcomes) to a greater extent than placebo over a ten week intervention phase in a parallel group design.


Recruitment information / eligibility

Status Recruiting
Enrollment 189
Est. completion date April 1, 2025
Est. primary completion date July 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Diagnosis of posttraumatic stress disorder (PTSD) according to DSM 5 with a 20 item CAPS-5 total score = 26 2. At least two nightmares a week, an intensity score = 2, with a CAPS-IV B2 (frequency and intensity for the last week) score = 5 3. Men and women between 18 and 65 years of age 4. Written informed consent 5. The patient has the capacity to give consent (He/she is able to understand the nature and anticipated effects/side effects of the proposed medical intervention) 6. The patient is not breastfeeding 7. Women of child-bearing potential must have a negative urine or serum pregnancy test 8. All participants must use highly effective contraception 9. The patient received stable pharmacological medication for at least 4 weeks or at least five times the value of a elimination half-life prior to study baseline (any changes in medication dose or frequency of therapy must be answered with no). Exclusion Criteria: 1. Disturbances of cardiac impulse formation and conduction, for example sick sinus syndrome or atrioventricular block second and third degree 2. Bradycardia, with a heart rate less than 50 beats per minute 3. Current major depressive episode and a MADRS score > 34 4. The patient does have a known allergy, hypersensitivity or contraindication against clonidine, doxazosin, or other types of quinazolines 5. History of severe orthostatic hypotension 6. Benign prostatic hyperplasia and concomitant congestion of the upper urinary tract, chronic urinary tract infection or bladder stones, hypotension (for benign prostate hyperplasia only) 7. Either overflow bladder or anuria with or without progressive renal insufficiency 8. Planned cataract surgery (risk of 'Intraoperative Floppy Iris Syndrome') 9. Intake of phosphodiesterase-5-inhibitors 10. Intake of methylphenidate 11. Severe hepatic impairment (ASAT or ALAT greater than two times normal) 12. Acute or unstable medical illness 13. Known HIV- and/or active Hepatitis-B- or Hepatitis-C-infection 14. Current or past malignant illness 15. The patient does have clinically significant abnormalities in 12-lead ECG 16. The patient does have clinically significant laboratory abnormalities 17. Epilepsy 18. Dementia 19. Current substance/alcohol use disorder (= 3 months) 20. Psychotic disorder 21. Bipolar disorder 22. Current anorexia nervosa 23. Acute suicidality (any suicidal ideation of type of 5 in the C-SSRS in the past month) 24. Intake of alpha adrenergic agents (Clonidine, doxazosin, or others) within 4 weeks prior to baseline (randomization) 25. Trauma-focused psychotherapy four weeks before the trial 26. Initiation of sleep medication 4 weeks prior to baseline 27. The patient is unwilling to consent to saving, processing and propagation of pseudonymized medical data for study reasons 28. Patients, who may be dependent on the sponsor, the investigator or the trial sites 29. The patient is legally detained in an official institution 30. The patient did participated in other interventional trials during the 3 months before and at the time of this trial

Study Design


Intervention

Drug:
Clonidine
All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 0.375 clonidine. Using capsules of 0,075 mg clonidine.
Doxazosin
All patients enrolled establish their individually tolerable dose by dose. Dosage up to a maximum of 10 mg doxazosin. Using capsules of 2 mg doxazosin. Titration.
Placebo
All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 5 capsules. Using capsules of placebo.

Locations

Country Name City State
Germany Berlin St. Hedwig Berlin
Germany Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Psychiatrie und Psychotherapie Berlin
Germany Universitätsklinikum Hamburg-Eppendorf Hamburg
Germany Zentralinstitut für Seelische Gesundheit Mannheim Mannheim

Sponsors (2)

Lead Sponsor Collaborator
Charite University, Berlin, Germany German Federal Ministry of Education and Research

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of frequency and intensity of nightmares Change of Frequency and intensity of nightmares, measured with the Clinician-Administered PTSD Scale-IV (CAPS-IV) B2 score for the last week, range 0-8, from baseline until directly after last intervention. A lower score indicates less frequent and/or intense nightmares. 10 weeks
Secondary Change of frequency and intensity of nightmares Change of Frequency and intensity of nightmares, measured with the Clinician-Administered PTSD Scale-IV (CAPS-IV) B2 score for the last week, range 0-8, from baseline until directly after last intervention. A lower score indicates less frequent and/or intense nightmares. 1,2,3,4,5,6 and 8 weeks
Secondary Change from baseline of the CAPS-5 total score Change from baseline of the CAPS-5 total score (overall PTSD symptoms, last week) 6 and 10 weeks
Secondary Change from baseline of the Pittsburgh Sleep Quality Index-Addendum for PTSD Change from baseline of the Pittsburgh Sleep Quality Index-Addendum for PTSD (PSQI A) (PTSD related sleep symptoms) 6 and 10 weeks
Secondary Change from baseline of the -Montgomery Asberg Depression Rating Scale Change from baseline of the -Montgomery Asberg Depression Rating Scale (MADRS) 6 and 10 weeks
Secondary Weekly mean of change from baseline of daily total sleep time Weekly mean of change from baseline of the patients daily total sleep time (in minutes), assessed with sleep diaries during 10 weeks
Secondary Weekly mean of change from baseline of the patients sleep onset latency at night (in minutes), assessed with sleep diaries Weekly mean of change from baseline of the patients sleep onset latency at night (in minutes), assessed with sleep diaries during 10 weeks
Secondary Weekly mean of change from baseline of the patients recuperation of night sleep Weekly mean of change from baseline of the patients recuperation of night sleep (5-point Likert scale, 1 = very much; 5
= not at all), assessed with sleep diaries
during 10 weeks
Secondary Weekly mean of change from baseline of the patients time awake at night Weekly mean of change from baseline of the patients time awake at night (in minutes), assessed with sleep diaries during 10 weeks
Secondary Weekly mean of change from baseline of the patients number of nightmares last night Weekly mean of change from baseline of the patients number of nightmares last night (0, 1, 3, 4 or more) assessed with sleep diaries during 10 weeks
Secondary Weekly mean of change from baseline of the patients intensity of nightmares Weekly mean of change from baseline of the patients intensity of nightmares (5-point Likert scale, 0 = not at all; 5 = extreme) assessed with sleep diaries during 10 weeks
Secondary Change from baseline of PTSD symptoms assessed with the PTSD Checklist for DSM-5 Change from baseline of PTSD symptoms assessed with the PTSD Checklist for DSM-5 (PCL-5) 6 and 10 weeks
Secondary Change from baseline of the Borderline Symptom List 23 Change from baseline of the Borderline Symptom List 23 (BSL-23) score 6 and 10 weeks
Secondary Change from baseline of the Health-Related Quality of Life Change from baseline of the Health-Related Quality of Life (EQ-5D) score 6 and 10 weeks
Secondary Overall patients status measured by the Patient Global Impression of Change Overall patients status measured by the Patient Global Impression of Change (PGIC) 6 and 10 weeks
Secondary Change from baseline of the Social and Occupational Functioning Assessment Scale Change from baseline of the Social and Occupational Functioning Assessment Scale (SOFAS) 6 and 10 weeks
Secondary Change from baseline of the Pittsburgh Sleep Quality Index Change from baseline of the Pittsburgh Sleep Quality Index (PSQI) 6 and 10 weeks
Secondary Change from baseline of symptoms of PTSD and complex PTSD according to ICD-11 assessed with the International Trauma Questionnaire Change from baseline of symptoms of PTSD and complex PTSD according to ICD-11 assessed with the International Trauma Questionnaire (ITQ) 6 and 10 weeks
Secondary Responder analysis: proportion of patients showing improvement in nightmares Responder analysis: proportion of patients showing improvement in nightmares (change from baseline) defined as decrease of CAPS-IV B2 =50% assessed at the end of treatment 10 weeks
Secondary Remitter analysis: proportion of patients showing full remission of nightmares Remitter analysis: proportion of patients showing full remission of nightmares defined as CAPS-IV B2 = 0, assessed at the end of treatment 10 weeks
See also
  Status Clinical Trial Phase
Completed NCT03384706 - A Comparison of CPT Versus ART Versus WL N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03129204 - Sensation Awareness Focused Training for Spouses N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Completed NCT05113277 - Development and Evaluation of a Tonic Immobility Focused Psychoeducational Intervention N/A
Recruiting NCT05327504 - Written Exposure Therapy for Veterans With SUD and PTSD N/A
Recruiting NCT05843695 - Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Completed NCT00644423 - Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD) N/A
Completed NCT02989987 - NET for SGBV Survivors in Eastern DR Congo N/A
Completed NCT02320799 - Randomized Controlled Trial of Interpersonal Psychotherapy for Depression and PTSD Among HIV+ Women in Kenya N/A
Recruiting NCT02293291 - Thermal Clinic Treatment in Gulf War Illness Phase 1/Phase 2
Completed NCT02242136 - Treatment of Posttraumatic Stress Disorder and Aggressive Behavior in Soldiers and Ex-combatants N/A
Completed NCT01911585 - Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure N/A
Completed NCT02720497 - The Efficacy of 90-Minute Versus 60-Minute Sessions of Prolonged Exposure for PTSD N/A
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Completed NCT01693978 - Contingency Outcomes in Prolonged Exposure N/A
Completed NCT01469754 - Longitudinal Survey Analysis in Lymphoma Survivors N/A
Completed NCT02362477 - Telemental Health and Cognitive Processing Therapy for Female Veterans With Military-related PTSD Phase 3
Terminated NCT01239173 - Emotional Memory Reactivation in Posttraumatic Stress Disorder Phase 3